Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Detecting failed WBC-reduction processes: a quality assurance program introduced in a blood center.

M R Adams1, N V Hirschler, L Papenfus

  • 1Department of Medicine, University of California, San Francisco, CA 94143-0532, USA. Barky106@hotmail.com

Transfusion
|January 3, 2001
PubMed
Summary

A new quality assurance (QA) system for white blood cell (WBC)-reduction processes in blood centers was developed. Statistical analysis determined the optimal sample size needed to ensure process reliability and detect failures effectively.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for New Resonances Decaying to Pairs of Merged Diphotons in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2025
Same author

Searches for Pair-Produced Multijet Resonances Using Data Scouting in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2024
Same author

Search for Soft Unclustered Energy Patterns in Proton-Proton Collisions at 13 TeV.

Physical review letters·2024
Same author

Search for the Z Boson Decay to ττμμ in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2024
Same author

Observation of the <math> </math> decay.

The European physical journal. C, Particles and fields·2024
Same author

Observation of Enhanced Long-Range Elliptic Anisotropies Inside High-Multiplicity Jets in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2024

Area of Science:

  • Blood banking and transfusion medicine
  • Biostatistics
  • Quality assurance

Background:

  • Effective quality assurance (QA) programs are crucial for blood centers to validate and monitor white blood cell (WBC)-reduction processes.
  • A novel QA system was developed, integrating statistical theory for practical application in a large blood center setting.
  • This system provides essential parameters for evaluating procedures and components, along with guidance on sample size and data formatting.

Purpose of the Study:

  • To develop and implement a statistically sound quality assurance (QA) program for white blood cell (WBC)-reduction processes.
  • To determine the appropriate sample sizes for validating and monitoring WBC-reduction processes, ensuring reliability and efficiency.
  • To establish guidelines for outlier evaluation and performance documentation within blood centers.

Related Experiment Videos

Main Methods:

  • Performance analyses of filtration and apheresis WBC-reduction processes were conducted between 1997 and 1999.
  • Statistical techniques, including parametric and nonparametric methods, were employed to determine necessary sample sizes.
  • Analyses focused on detecting failures in platelet yield, unit volume, pH, and WBC count.

Main Results:

  • Parametric analysis proved sensitive to normally distributed shifts but less effective for unknown distributions.
  • Nonparametric analysis indicated a minimum sample size of 40 is required for high confidence in detecting significant bimodal WBC failure.
  • The study established sample sizes for achieving appropriate confidence and tolerance levels in process evaluation.

Conclusions:

  • A robust QA system was developed, utilizing statistical analysis for both normal and non-normal process failure distributions.
  • The system effectively determines sample sizes for achieving desired confidence and tolerance levels in WBC-reduction processes.
  • Further research is recommended to address donor/component variability and identify key failure modes for enhanced blood center quality goals.